We are a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 250 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.

These products include a novel oral therapy for inflammatory bowel disease which is Phase III in the US & Europe; a novel oral selective c-Met inhibitor in phase II in Australia, China & the United States; four differentiated oral NCEs in oncology in Phase I & Phase II in China; and one oral NCE for inflammation in Phase I in Australia. Multiple NCEs are also in preclinical development.

After founding the company in 2002, we have built one of the largest and most experienced new drug R&D teams in China. We are led by a strong senior management team, all of whom have many years of experience succeeding at large US pharmaceutical and biotech companies. Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono and Nestlé Health Science in both oncology and inflammation.

和记黄埔医药（上海）有限公司（以下称“和记黄埔医药”）是中国最为领先的新药研发企业之一。公司致力于研发具有自主知识产权保护的治疗癌症和自身免疫性疾病的创新药物。目前公司共有研发人员250余名。

和记黄埔医药的在研新药包括：在美国和欧洲进入临床三期试验的用于治疗溃疡性结肠炎的新型口服药物；在澳大利亚、中国和美国进行临床二期试验的新型抗癌药物c-Met口服抑制剂；在中国进行临床一期和二期试验的四个小分子口服肿瘤抑制剂；在澳大利亚进行临床一期试验的炎症领域新型口服小分子药物以及多个处于临床前研究阶段的小分子药物。

和记黄埔医药成立于2002年，经过多年发展，逐渐发展成为中国最大、最有经验的新药研发企业之一。公司拥有一流的创新药物研发管理团队，管理团队成员皆有在美国大型制药公司或生物公司的管理经验。近几年来，和记黄埔医药与全球知名医药研发机构如雀巢、阿斯利康、美国强生、美国礼来等建立了战略合作伙伴关系，共同研发造福于全球病患的创新药物。

www.hmplglobal.com
www.Chi-med.com